Vertaling van "these products " (Nederlands → Frans) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat barbituraat bevat
produit contenant du barbiturique

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat baricitinib bevat
produit contenant du baricitinib

IN-CONTEXT TRANSLATIONS

These remain top priorities for the strengthened leadership team of Novartis in 2009 with targets set to deliver superior growth, achieve more productivity gains, further improve cash flow management and bolster the product portfolio.
Ces facteurs demeurent des priorités absolues pour l’équipe dirigeante renforcée de Novartis en 2009. Ses objectifs sont de réaliser une forte croissance, d'engendrer de nouveaux gains de productivité, d’améliorer encore la gestion des flux de trésorerie et de développer le portefeuille de produits.

Thanks to the introduction of a proactive vigilance policy within the FAMHP via the PROACTIVE VIGILANCE spearhead, the safety profile of medicines and health products will be better known, thereby also promoting safer use of these products.
Thanks to the introduction of a proactive vigilance policy within the FAMHP via the PROACTIVE VIGILANCE spearhead, the safety profile of medicines and health products will be better known, thereby also promoting safer use of these products.

These impacts however were more than offset by a number of positive factors, including: Marketing & Sales costs, which were lower by 0.4 percentage points due to productivity improvements partly offset by investments in growth areas; R&D costs, which decreased (improving +1.2 percentage points) as productivity savings funded continued investment in the development of differentiated generics; General & Administration costs, which decreased (+1.1 percentage points) due to ongoing cost reduction measures; and Other Income and Expenses, which were positive at 0.5 percentage points due to lower legal fees.
Cependant, ces impacts ont été plus que compensés par un certain nombre de facteurs positifs, notamment: une baisse de 0,4 point de pourcentage des coûts de Marketing et vente due à des gains de productivité en partie contrebalancés par des investissements dans des domaines en pleine croissance; une diminution des coûts de Recherche et développement (amélioration +1,2 point), des gains de productivité servant à financer des investissements continus dans le développement de génériques différenciés; un abaissement des coûts d’Administration et frais généraux (+1,1 point) grâce à des mesures continues de réduction des coûts; une progression de 0,5 point d'Autres produits et charges suite à une baisse des frais juridiques.

These priorities, aimed at creating greater value for patients, payors and physicians, include (1) extending the Group’s lead in innovation; (2) delivering sustainable growth through successful new product launches, investments to strengthen the business portfolio, and expansion in emerging markets; and (3) productivity initiatives that free up resources to improve profitability and support investments in innovation and growth.
Ces priorités, visant à créer une plus-value plus importante pour les malades, les payeurs et les médecins, comprennent 1) l’accroissement de l’avance du Groupe dans l’innovation, 2) la réalisation d’une croissance durable par le lancement de nouveaux produits et des investissements pour renforcer le portefeuille d’activités et s’étendre dans les marchés émergents et 3) la réalisation de projets destinés à accroître la productivité de manière à libérer des ressources pour améliorer la profitabilité et soutenir les investissements dans l'innovation et la croissance.

The cases dealt with in these meetings may be complaints by consumers or producers, requests for advice from inspection services, formal opinions on the formulation of regulations, formal opinions for companies wishing to market products and to ensure that they are presenting their product correctly, and internal cases that serve for the compilation of guidelines for the consultation platform.
The cases dealt with in these meetings may be complaints by consumers or producers, requests for advice from inspection services, formal opinions on the formulation of regulations, formal opinions for companies wishing to market products and to ensure that they are presenting their product correctly, and internal cases that serve for the compilation of guidelines for the consultation platform.

Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).
Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).

It is important that the most promising products are identified so that available means (such as time, trial animals, working time, money) can quickly be concentrated on further development of these products.
It is important that the most promising products are identified so that available means (such as time, trial animals, working time, money) can quickly be concentrated on further development of these products.

This article stipulates The regulation states that production, quality and pharmacovigilance standards need to be determined for these products;
This article stipulates The regulation states that production, quality and pharmacovigilance standards need to be determined for these products;

The safety and efficacy of medicines and health products are closely associated with the correct use of these products.
The safety and efficacy of medicines and health products are closely associated with the correct use of these products.

Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.
Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.